BioNose

Intranasal administration is non-invasive and allows the delivery of drugs for different indications. In the development of new intranasal drugs, animals are often used to predict the behaviour of the therapeutic molecule in humans. It is now recognised that animal models, while still necessary, lack predictability. They are also increasingly challenged by ethical pressures. In the field of intranasal products, stereolithographed 3D anatomical models have become the tool of choice to study and predict drug deposition in the nasal cavity and to optimise medical devices. However, their inert nature makes them unsuitable for pharmacological studies. The BioNose project proposes to develop an innovative biomimetic model of the human nasal cavity. This model will be based on 'nose-on-chip' and 3D stereolithography technologies, with the aim of accelerating the development of nasal drugs. In addition, this non-animal model is part of an ethical approach respecting the principle of the 3Rs.